Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Pilot Study of ARC1779 Injection in von Willebrand Factor-Related Platelet Function Disorders
2007-004371-19Phase 2Completed
- Sponsor
- Archemix Corp.
- Start
- Dec 2007
- Modality
- RNA Aptamers → RNA Therapeutics → Nucleic Acid Therapeutics, DNA Aptamers → DNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, single-arm trial of egaptivon pegol in thrombotic thrombocytopenic purpura (TTP) and von Willebrand disease (VWD), sponsored by Archemix Corp. Primary endpoints: Safety Variables, Pharmacokinetics of ARC1779 and 1 more. Started Dec 2007; status: completed.
02
Drugs
egaptivon pegol
03
Conditions
thrombotic thrombocytopenic purpura (TTP)von Willebrand disease (VWD)
Beyond the preview
Go deeper on 2007-004371-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004371-19.